All In Biotech

Drug Trial Radar · NCT04759131

Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A

A Phase 3 Open-label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; BIVV001) in Previously Treated Pediatric Patients <12 Years of Age With Severe Hemophilia A

Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

74

Actual

Start

Feb 19, 2021

Primary completion

Jan 18, 2023

Study completion Jan 18, 2023

Sponsor

Lead sponsor
Bioverativ, a Sanofi companySanofi (SNY)
Sponsor type
Industry
First posted
Feb 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: \- To evaluate the safety of BIVV001 in previously treated pediatric participants with hemophilia A. Secondary Objectives: * To evaluate the efficacy of BIVV001 as a prophylaxis treatment. * To evaluate the efficacy of BIVV001 in the treatment of bleeding episodes. * To evaluate BIVV001 consumption for prevention and treatment of bleeding episodes. * To evaluate the effect of BIVV001 prophylaxis on joint health outcomes. * To evaluate the effect of BIVV001 prophylaxis on Quality of Life (QoL) outcomes. * To evaluate the efficacy of BIVV001 for perioperative management. * To evaluate the safety and tolerability of BIVV001 treatment. * To assess the pharmacokinetics (PK) of BIVV001.

Conditions

  • Hemophilia A

Interventions

  • efanesoctocog alfa (BIVV001)Drug

    Pharmaceutical form: solution for injection Route of administration: IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Neutralising Antibodies (Development of Inhibitors) Directed Against Factor VIIITime frame: Baseline up to Week 52

Locations

40 sites in 15 countries. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles-Site Number:8400006

    Los Angeles, California

  • University of Florida-Site Number:8400009

    Gainesville, Florida

  • Children's Healthcare of Atlanta-Site Number:8400019

    Atlanta, Georgia

  • Rush University Medical Center-Site Number:8400001

    Chicago, Illinois

  • University of Iowa Hospitals and Clinics-Site Number:8400002

    Iowa City, Iowa

  • NY Presbyterian - Weill Cornell Medical Center-Site Number:8400020

    New York, New York

  • East Carolina University/Brody Medical Sciences Building-Site Number:8400015

    Greenville, North Carolina

  • Cincinnati Children's Hospital Medical Center-Site Number:8400008

    Cincinnati, Ohio

  • Childrens Hospital Of Columbus-Site Number:8400012

    Columbus, Ohio

  • Children's Hospital Of Wisconsin-Site Number:8400005

    Milwaukee, Wisconsin

  • Investigational Site Number :0360001

    Westmead, New South Wales, Australia

  • Investigational Site Number :0360002

    South Brisbane, Queensland, Australia

  • Investigational Site Number :1240004

    Hamilton, Ontario, Canada

  • Investigational Site Number :1240003

    London, Ontario, Canada

  • Investigational Site Number :1240002

    Ottawa, Ontario, Canada

  • Investigational Site Number :1240001

    Toronto, Ontario, Canada

  • Investigational Site Number :2500004

    Bron, France

  • Investigational Site Number :2500001

    Le Kremlin-Bicêtre, France

  • Investigational Site Number :2500003

    Lille, France

  • Investigational Site Number :2760001

    Frankfurt am Main, Germany

  • Investigational Site Number :2760002

    München, Germany

  • Investigational Site Number :3480005

    Pécs, Hungary

  • Investigational Site Number :3720001

    Dublin, Ireland

  • Investigational Site Number :3800001

    Milan, Italy

  • Investigational Site Number :3800002

    Naples, Italy

  • Investigational Site Number :5280002

    Amsterdam, Netherlands

  • Investigational Site Number :5280001

    Utrecht, Netherlands

  • Investigational Site Number :7240002

    Esplugues de Llobregat, Catalunya [Cataluña], Spain

  • Investigational Site Number :7240001

    Madrid, Madrid, Comunidad de, Spain

  • Investigational Site Number :7520001

    Malmö, Sweden

  • Investigational Site Number :7560001

    Zurich, Switzerland

  • Investigational Site Number :1580001

    Taichung, Taiwan

  • Investigational Site Number :1580003

    Taichung, Taiwan

  • Investigational Site Number :1580002

    Taipei, Taiwan

  • Investigational Site Number :1580004

    Taipei, Taiwan

  • Investigational Site Number :7920004

    Antalya, Turkey (Türkiye)

  • Investigational Site Number :7920001

    Istanbul, Turkey (Türkiye)

  • Investigational Site Number :7920003

    Izmir, Turkey (Türkiye)

  • Investigational Site Number :8260003

    Birmingham, United Kingdom

  • Investigational Site Number :8260001

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.